Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.

The efficacy and safety of the oral factor Xa inhibitor edoxaban compared to warfarin stratified by CHA The ENGAGE AF-TIMI 48 trial randomized patients with atrial fibrillation to once-daily edoxaban or warfarin. We classified patients based on CHA The distribution CHA The benefit and safety of edoxaban versus warfarin is maintained across CHA

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors report the following potential conflicts of interest: Dr. De Groot - research grant through his institution: Abbott, Atricure, Bayer, Boston Scientific, Daiichi Sankyo, Johnson&Johnson, Medtronic. Honoraria for scientific advisory boards and consulting: Atricure, Bayer, Daiichi Sankyo, Johnson&Johnson, Medtronic, Novartis, Servier. Dr. Ruff - research grants through institution: Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, National Institutes of Health. Honoraria for scientific advisory boards and consulting: Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Pfizer, Portola. Dr. Murphy - research grants from Abbott Laboratories, Amarin, Amgen, AstraZeneca, Critical Diagnostics, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia Therapeutics, Merck and Co., Roche Diagnostics, Takeda, Gilead, Poxel, Novartis, MedImmune, Janssen Research Development, and Genzyme. Ms. Hamershock - grant support through her institution rom Daiichi Sankyo. Dr. Vehmeijer nothing to report. Dr. Oude Ophuis - grant support to his institution from Daiichi Sankyo, personal fees from TIMI during the conduct of the study; grant support and personal fees from Boston Scientific and Abbott; personal fees from AstraZeneca and Merck Sharp & Dohme; and nonfinancial support from Biosensor, WCN, and Vascular Research Network outside the submitted work. Ms. Grip - grant support through her institution from Daiichi Sankyo. Dr. Lanz - employment at Daiichi Sankyo. Dr. Mercuri - employment at Daiichi Sankyo. Dr. Antman - grant support through his institution from Daiichi Sankyo. Dr. Giugliano - grant support through his institution from Daiichi Sankyo and Anthos; personal fees for CME lectures and/or consulting from Boheringer-Ingelheim, Bristol-Myers-Squibb, CryoLife, Daiichi Sankyo, Eli Lilly and Company, Janssen, Merck, Pfizer, SAJA Pharmaceuticals and Servier. Drs. Ruff, Antman, and Giugliano and Ms Murphy, Hamershock and Grip report Institutional research grant to the TIMI Study Group at Brigham and Women's Hospital for research they are not directly involved in from Abbott, Amgen, Anthos, Aralez, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research and Development, Medicines Company, MedImmune, Merck, Novartis, Poxel, Pfizer, Quark Pharmaceuticals, Regeneron, Roche, Siemens, Takeda, The Medicines Company, Zora Biosciences.